GLP-1 weight-loss medications show no link to suicide risk

A study published in the journal Diabetology, conducted by researchers from New Mexico State University and the University of Nevada, Las Vegas, indicates that GLP-1 receptor agonists—popularly known as “weight-loss pens” such as Mounjaro, Ozempic, and Wegovy—are not associated with increased suicidal thoughts, depression, or other serious psychiatric damage.

Following initial reports of potential psychiatric side effects, regulatory bodies including the FDA and EMA conducted safety reviews. The FDA has since removed the suicide risk warning from the labels of these medications. Researchers noted that early reports were based on voluntary observations from patients and doctors, which did not hold up under subsequent large-scale studies involving millions of patients.

Separately, medical experts have raised concerns regarding the physical and psychological risks of obesity treatments. Endocrinologist Isabel do Carmo warns that while these medications are effective, they may lead to nutritional deficiencies, loss of muscle mass, and the aggravation of eating disorders such as anorexia and orthorexia. She noted that extreme calorie restriction can result in fatigue, hair loss, and weakened skin due to insufficient intake of essential vitamins and minerals.